“The approval of COVAXIN for emergency use is a giant leap for Innovation and novel product development in India,” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said.
Expressing delight on the Ministry of Health & Family Welfare announcement and the statement from DCGI-Central Standards Control Organization grant of permission for emergency use of its Covid-19 vaccine today, Ella in a statement said, “It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN has generated excellent safety data with robust immune responses to multiple viral proteins that persist.”
“The development of COVAXIN was truly a public private partnership between ICMR, NIV and Bharat Biotech, we sincerely thank the Director General ICMR, Dr. Balram Bhargava for his visionary leadership in this project,” he said.
The Subject Expert Committee of Central Drugs Standards Control Organization made the recommendations for the consideration and final decision of the Drugs Controller General of India.
COVAXIN is a highly purified and inactivated 2 dose SARS-CoV2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses.
COVAXIN Phase III clinical trials
The Phase III human clinical trials of COVAXIN began mid-November, targeted to be done in 26,000 volunteers across India, This is India’s first and only Phase III efficacy study for a COVID-19 vaccine, and the largest phase III efficacy trial ever conducted for any vaccine in India. It has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results.
Developed in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV), COVAXIN is indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.
The evaluation of COVAXIN has resulted in several unique product characteristics including long term persistence of immune responses to multiple viral proteins, as opposed to only the spike protein. It demonstrated broad spectrum neutralizing capability with heterologous SARS-CoV2 strains, thus potentially reducing or eliminating escape mutants. It has also shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. Its most critical characteristic is the demonstrated safety profile, which is significantly lower than several other vaccines with published data.
The product development and clinical trial data thus far has generated 5 publications, which have been submitted to international peer reviewed journals, 4 of which have been accepted and will be published soon. The publication of phase II trial data is undergoing the peer review process.
As a part of our regulatory guidelines, all data has been submitted to the DCGI and CDSCO.